J McNeill

University of British Columbia - Vancouver, Vancouver, British Columbia, Canada

Are you J McNeill?

Claim your profile

Publications (1)2.06 Total impact

  • Article: Endothelin-1 modulates angiotensin II in the development of hypertension in fructose-fed rats.
    L T Tran, K M MacLeod, J H McNeill
    [show abstract] [hide abstract]
    ABSTRACT: Two of the most potent vasoconstrictors, endothelin-1 (ET-1) and angiotensin II (Ang II), are upregulated in fructose hypertensive rats. It is unknown whether an interrelationship exists between these peptides that may contribute to the development of fructose-induced hypertension. The objective of this study was to investigate the existence of an interaction between the endothelin and renin angiotensin systems that may play a role in the development of fructose-induced hypertension. High fructose feeding and treatment with either bosentan, a dual endothelin receptor antagonist, or with L-158,809, an angiotensin type 1 receptor antagonist, were initiated simultaneously in male Wistar rats. Systolic blood pressure, fasted plasma parameters, insulin sensitivity, plasma Ang II, and vascular ET-1-immunoreactivity were determined following 6 weeks of high fructose feeding. Rats fed with a high fructose diet exhibited insulin resistance, hyperinsulinemia, hypertriglyceridemia, hypertension, and elevated plasma Ang II. Treatment with either bosentan or L-158,809 significantly attenuated the rise in blood pressure with no effect on insulin levels or insulin sensitivity in fructose-fed rats. Bosentan treatment significantly reduced plasma Ang II levels, while L-158,809 treatment significantly increased vascular ET-1-immunoreactivity in fructose-fed rats. Thus, treatment with the endothelin receptor antagonist prevented the development of fructose-induced hypertension and decreased plasma Ang II levels. These data suggest that ET-1 contributes to the development of fructose-induced hypertension through modulation of Ang II levels.
    Molecular and Cellular Biochemistry 02/2009; 325(1-2):89-97. · 2.06 Impact Factor

Institutions

  • 2009
    • University of British Columbia - Vancouver
      • Faculty of Pharmaceutical Sciences
      Vancouver, British Columbia, Canada